文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

基因编辑挽救与先天性无巨核细胞性血小板减少症相关的新型MPL突变

Gene editing rescue of a novel MPL mutant associated with congenital amegakaryocytic thrombocytopenia.
PubMed 文献 · Blood Adv · 2017-09-22

本文报告了携带未报道的MPL T814C(W272R)突变(背景为激活性MPL G117T即K39N或Baltimore突变)的家族性先天性无巨核细胞性血小板减少症(CAMT)病例。研究发现W272R突变型Mpl蛋白(单独或与K39N共存)无表面表达且滞留于内质网,对Tpo无反应。通过GRASP55过表达或CRISPR-Cas9基因编辑修复MPL T814C突变,可部分恢复突变受体功能,在原发性造血干细胞中验证了基因编辑挽救的可行性。

要点

  • 新型MPL T814C(W272R)突变导致Mpl蛋白滞留内质网、无表面表达且对Tpo无反应。
  • GRASP55过表达通过激活自噬依赖性分泌途径部分恢复突变Mpl的Tpo诱导信号。
  • CRISPR-Cas9基因编辑修复MPL T814C突变可在原代脐带血CD34+细胞中挽救受体功能。

核心结论

  • 在原发性造血干细胞中基因编辑修复MPL突变可挽救受体功能,为CAMT患者提供直接治疗应用的概念验证。

研究设计与样本

  • 本文报告家族性CAMT病例,采用共聚焦显微镜、增殖与表面生物素化实验、免疫共沉淀及蛋白质印迹分析研究Mpl突变体的功能与转运。
  • 利用CRISPR-Cas9基因编辑在转染细胞系和原代脐带血来源CD34+细胞中修复MPL T814C突变。

主要发现

  • 携带W272R突变的Mpl蛋白(单独或与K39N突变共存)无 detectable 表面表达,并与内质网标志物钙网蛋白强共定位。
  • 野生型和K39N突变型Mpl均具有信号传导能力,但携带W272R的单突变或双突变体对Tpo无反应。
  • GRASP55过表达通过激活自噬依赖性分泌途径,迫使内质网滞留的未成熟受体转运至细胞表面,部分恢复突变Mpl的Tpo诱导信号。
  • CRISPR-Cas9基因编辑修复MPL T814C突变可在转染细胞系和原代脐带血来源CD34+细胞中实现。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thrombopoietin (Tpo) and its receptor (Mpl) are the principal regulators of early and late thrombopoiesis and hematopoietic stem cell maintenance. Mutations in MPL can drastically impair its function and be a contributing factor in multiple hematologic malignancies, including congenital amegakaryocytic thrombocytopenia (CAMT). CAMT is characterized by severe thrombocytopenia at birth, which progresses to bone marrow failure and pancytopenia. Here we report unique familial cases of CAMT that presented with a previously unreported MPL mutation: T814C (W272R) in the background of the activating MPL G117T (K39N or Baltimore) mutation. Confocal microscopy, proliferation and surface biotinylation assays, co-immunoprecipitation, and western blotting analysis were used to elucidate the function and trafficking of Mpl mutants. Results showed that Mpl protein bearing the W272R mutation, alone or together with the K39N mutation, lacks detectable surface expression while being strongly colocalized with the endoplasmic reticulum (ER) marker calreticulin. Both WT and K39N-mutated Mpl were found to be signaling competent, but single or double mutants bearing W272R were unresponsive to Tpo. Function of the deficient Mpl receptor could be rescued by using 2 separate approaches: (1) GRASP55 overexpression, which partially restored Tpo-induced signaling of mutant Mpl by activating an autophagy-dependent secretory pathway and thus forcing ER-trapped immature receptors to traffic to the cell surface; and (2) CRISPR-Cas9 gene editing used to repair MPL T814C mutation in transfected cell lines and primary umbilical cord blood-derived CD34+ cells. We demonstrate proof of principle for rescue of mutant Mpl function by using gene editing of primary hematopoietic stem cells, which indicates direct therapeutic applications for CAMT patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Cleyrat C, Girard R, Choi EH, et al. Gene editing rescue of a novel MPL mutant associated with congenital amegakaryocytic thrombocytopenia. Blood Adv. 2017. PMID: 29296828. doi:10.1182/bloodadvances.2016002915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。